Floatz logo

Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]-

Solid Tumors, Adult

Ikena OncologySmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Solid Tumors, Adult cohort.

Asset / SponsorPhaseRating
Ribociclib
Eli Lilly and Company
Phase 1/2CC
TAMOXIFEN
Eli Lilly and Company
Phase 1/2CC
Letrozole
Eli Lilly and Company
Phase 1/2CC
Zoladex
Eli Lilly and Company
Phase 1/2CC
Cyclophosphamide
Tango Therapeutics, Inc.
Phase 1/2CC

View all 38 →

Same molecule, other indications

Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- is also rated in:

malignant pleural mesotheliomaDormant
CC
Indicative ·
43 / 100
View asset →
epithelioid hemangioendotheliomaDormant
CC
Indicative ·
43 / 100
View asset →
mesotheliomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →